Federal Circuit sides with Bayer and Endo in testosterone case

16-07-2018

Federal Circuit sides with Bayer and Endo in testosterone case

scyther5 / iStockphoto.com

The US Court of Appeals for the Federal Circuit confirmed the validity of two patents covering a testosterone replacement therapy on Friday, July 13, in a win for Bayer Pharma and Endo Pharmaceuticals Solutions.


Bayer, Endo, Custopharm, patent invalidation, patent infringement, US Court of Appeals for the Federal Circuit, testosterone, ANDA, new drug

LSIPR